Skip to main content
Home > Week in Review > Clinical Results

Chronological Index of : Clinical Results

 Current Issue
  • AG-348: Phase II data

    Agios Pharmaceuticals Inc. (NASDAQ:AGIO), Cambridge, Mass. Product: AG-348 Business: Endocrine/Metabolic Molecular target: Pyruvate kinase R Description: Oral small molecule activator of pyruvate kinase R Indication: …

    Published on 6/20/2016
  • ALXN1210: Preliminary Phase I/II data

    Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), Cheshire, Conn. Product: ALXN1210 Business: Hematology Molecular target: Complement 5 (C5) Description: Long-acting humanized mAb against complement 5 (C5) Indication: Treat …

    Published on 6/20/2016
  • AM0010: Additional Phase I data

    Armo BioSciences Inc., Redwood City, Calif. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Product: AM0010 Business: Cancer Molecular target: Interleukin-10 (IL-10) Description: Pegylated form of recombinant IL-10 …

    Published on 6/20/2016
  • Anti-CD19 chimeric antigen receptor: Updated Phase I data

    Kite Pharma Inc. (NASDAQ:KITE), Los Angeles, Calif. Product: Anti-CD19 chimeric antigen receptor (CAR) T cells Business: Cancer Molecular target: CD19 Description: Human chimeric antigen receptor (CAR) T cells targeting…

    Published on 6/20/2016
  • Autologous T cell therapy against CD19: Updated Phase I/II data

    Kite Pharma Inc. (NASDAQ:KITE), Los Angeles, Calif. Product: Autologous T cell therapy against CD19 (KTE-C19) Business: Cancer Molecular target: CD19 Description: Autologous T cells genetically modified to express a …

    Published on 6/20/2016
  • BGB324: Phase I data

    BerGenBio A/S, Bergen, Norway Rigel Pharmaceuticals Inc. (NASDAQ:RIGL), South San Francisco, Calif. Product: BGB324 (formerly R428) Business: Cancer Molecular target: AXL receptor tyrosine kinase (AXL) (UFO) Description…

    Published on 6/20/2016
  • Biosimilar adalimumab: Additional Phase III data

    Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Samsung Group, Seoul, South Korea Product: Biosimilar adalimumab (SB5) Business: Autoimmune Molecular target: Tumor necrosis …

    Published on 6/20/2016
  • Biosimilar etanercept: Extension study data

    Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Samsung Group, Seoul, South Korea Product: Biosimilar etanercept (Brenzys, Benepali) (SB4) Business: Autoimmune Molecular target:…

    Published on 6/20/2016
  • Biosimilar infliximab: Additional Phase III data

    Biogen Inc. (NASDAQ:BIIB), Cambridge, Mass. Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Samsung Group, Seoul, South Korea Product: Biosimilar infliximab (Flixabi, Renflexis) (SB2) Business: Autoimmune Molecular target…

    Published on 6/20/2016
  • Blincyto blinatumomab: Additional Phase III data

    Amgen Inc. (NASDAQ:AMGN), Thousand Oaks, Calif. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Product: Blincyto blinatumomab (AMG 103) (formerly MT103) Business: Cancer Molecular target: CD19 Description: Bispecific T…

    Published on 6/20/2016
  • DaxibotulinumtoxinA Topical Gel: Phase III data

    Revance Therapeutics Inc. (NASDAQ:RVNC), Newark, Calif. Product: DaxibotulinumtoxinA Topical Gel (RT001, RTT150) Business: Dermatology Molecular target: NA Description: Topical gel formulation of botulinum toxin type A …

    Published on 6/20/2016
  • Duvelisib: Phase II data

    Infinity Pharmaceuticals Inc. (NASDAQ:INFI), Cambridge, Mass. AbbVie Inc. (NYSE:ABBV), Chicago, Ill. Takeda Pharmaceutical Co. Ltd. (Tokyo:4502), Osaka, Japan Product: Duvelisib (IPI-145) (formerly INK-1197) Business: …

    Published on 6/20/2016
  • Ertugliflozin: Phase III data

    Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Ertugliflozin (MK-8835, PF-4971729, PF-04971729) Business: Endocrine/Metabolic Molecular target: Sodium-glucose cotransporter…

    Published on 6/20/2016
  • Ertugliflozin: Phase III data

    Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Pfizer Inc. (NYSE:PFE), New York, N.Y. Product: Ertugliflozin (MK-8835, PF-4971729, PF-04971729) Business: Endocrine/Metabolic Molecular target: Sodium-glucose cotransporter…

    Published on 6/20/2016
  • Ganaxolone: Phase III data

    Marinus Pharmaceuticals Inc. (NASDAQ:MRNS), Radnor, Pa. Product: Ganaxolone (CCD-1042) Business: Neurology Molecular target: GABA A receptor Description: Synthetic analog of the endogenous neurosteroid allopregnanolone,…

    Published on 6/20/2016
  • GBT440: Additional Phase I/II data

    Global Blood Therapeutics Inc. (NASDAQ:GBT), South San Francisco, Calif. Product: GBT440 Business: Hematology Molecular target: Hemoglobin Description: Allosteric modifier of hemoglobin oxygen affinity Indication: Treat…

    Published on 6/20/2016
  • GPX-150: Preliminary Phase II data

    Gem Pharmaceuticals LLC, Pelham, Ala. Product: GPX-150 Business: Cancer Molecular target: NA Description: Non-cardiotoxic anthracycline derivative compound Indication: First-line treatment of soft tissue sarcoma (STS) …

    Published on 6/20/2016
  • IV BAL101553: Additional Phase I/IIa data

    Basilea Pharmaceutica AG (SIX:BSLN), Basel, Switzerland Product: IV BAL101553 Business: Cancer Molecular target: Tubulin Description: Water-soluble prodrug of BAL27862, an apoptosis-inducing small molecule targeting …

    Published on 6/20/2016
  • JCAR017: Additional Phase I/II data

    Celgene Corp. (NASDAQ:CELG), Summit, N.J. Juno Therapeutics Inc. (NASDAQ:JUNO), Seattle, Wash. Product: JCAR017 Business: Cancer Molecular target: CD19 Description: Autologous T cells expressing a chimeric antigen …

    Published on 6/20/2016
  • Keytruda pembrolizumab: Phase III data

    Merck & Co. Inc. (NYSE:MRK), Kenilworth, N.J. Product: Keytruda pembrolizumab (MK-3475) Business: Cancer Molecular target: Programmed cell death 1 (PD-1) (PDCD1) (CD279) Description: Humanized IgG4 mAb against PD-1 …

    Published on 6/20/2016
  • Omadacycline: Phase III data

    Paratek Pharmaceuticals Inc. (NASDAQ:PRTK), Boston, Mass. Product: Omadacycline (formerly PTK 0796) Business: Infectious Molecular target: Ribosomal 30S subunit Description: Aminomethylcycline antibiotic Indication: …

    Published on 6/20/2016
  • PRN1371: Phase I data

    Principia Biopharma Inc., South San Francisco, Calif. Product: PRN1371 Business: Cancer Molecular target: Fibroblast growth factor (FGF) receptor (FGFR) Description: Fibroblast growth factor (FGF) receptor (FGFR) …

    Published on 6/20/2016
  • TNT009: Interim Phase Ib data

    True North Therapeutics Inc., South San Francisco, Calif. Product: TNT009 Business: Hematology Molecular target: Complement component 1 s subcomponent (C1S) Description: Humanized mAb against complement component 1 s …

    Published on 6/20/2016
  • Viagenpumatucel-L: Phase Ib/II data

    Heat Biologics Inc. (NASDAQ:HTBX), Durham, N.C. Product: Viagenpumatucel-L (HS-110) Business: Cancer Molecular target: Heat shock 90 kDa protein beta 1 (Hsp90B1) (GP96) (GRP94) Description: Vaccine comprising lung …

    Published on 6/20/2016
  • Victoza liraglutide: Additional Phase III data

    Novo Nordisk A/S (CSE:NVO; NYSE:NVO), Bagsvaerd, Denmark Product: Victoza liraglutide (NN2211) Business: Endocrine/Metabolic Molecular target: Glucagon-like peptide-1 receptor (GLP-1R) (GLP1R) Description: Long-acting …

    Published on 6/20/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993